The OXiGENE Inc (NASDAQ:OXGN) on Mar. 11 announced positive results from a randomized Phase 2 clinical trial evaluating Avastin(R) (bevacizumab) with or without ZYBRESTAT(R) (fosbretabulin; CA4P) to treat patients with recurrent ovarian cancer. The study, known as Gynecologic Oncology Group protocol 186I, met its primary endpoint of a statistically significant increase in progression-free survival (p-value less than 0.05; hazard ratio 0.685) for the combination as compared to bevacizumab alone. The Phase 2 study is being conducted by the GOG under the sponsorship of the Cancer Therapy Evaluation Program (CTEP) of the National Cancer Institute (NCI). OXiGENE Inc (NASDAQ:OXGN) shares after opening at $3.80 moved to $3.48 on last trade day and at the end of the day closed at $3.48. Company price to sales ratio in past twelve months was calculated as 91.87 and price to cash ratio as 1.04. OXiGENE Inc (NASDAQ:OXGN) showed a negative weekly performance of -12.78%.
Biogen Idec (NASDAQ:BIIB) EVP Douglas E. Williams sold 3,505 shares of Biogen Idec stock in a transaction that occurred on Wednesday, March 19th.The shares were sold at an average price of $352.29, for a total value of $1,234,776.45. Following the completion of the sale, the executive vice president now directly owns 7,976 shares in the company, valued at approximately $2,809,865.Biogen Idec Inc (NASDAQ:BIIB) shares fell -8.22% in last trading session and ended the day on $318.53. BIIB return on equity ratio is recorded as 23.30% and its return on assets is 16.90%. Biogen Idec Inc (NASDAQ:BIIB) yearly performance is 80.42%.
The Celldex Therapeutics, Inc. (NASDAQ:CLDX) on Mar. 3 reported business and financial highlights for the fourth quarter and year ended December 31, 2013 and outlined the Company’s major clinical development goals for 2014. Total revenue was $0.6 million in the fourth quarter of 2013 and $4.1 million for the twelve months ended December 31, 2013, compared to $3.6 million and $11.2 million for the comparable periods in 2012. Net loss was $22.1 million, or ($0.27) per share, for the fourth quarter of 2013 and $81.6 million, or ($1.02) per share, for the twelve months ended December 31, 2013, compared to net loss of $16.8 million, or ($0.27) per share, and $59.1 million, or ($1.02) per share, for the comparable periods in 2012. Celldex Therapeutics, Inc. (NASDAQ:CLDX) shares moved down -9.54% in last trading session and was closed at $21.52, while trading in range of $21.32-$23.90.Celldex Therapeutics, Inc. (NASDAQ:CLDX) year to date performance is -11.11%.
Alexion Pharmaceuticals had its price target raised by analysts at UBS AG from $185.00 to $202.00. They now have a “buy” rating on the stock.Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) weekly performance is -8.84%. On last trading day company shares ended up $159.79.Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) distance from 50-day simple moving average is -1.43%. Analysts mean target price for the company is $190.36.